Patents by Inventor Colin Richard Dorgan
Colin Richard Dorgan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9763925Abstract: Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.Type: GrantFiled: March 8, 2016Date of Patent: September 19, 2017Assignee: SUMMIT THERAPEUTICS PLCInventors: Francis Xavier Wilson, Peter David Johnson, Richard Vickers, Richard Storer, Graham Michael Wynne, Alan Geoffrey Roach, Olivier De Moor, Colin Richard Dorgan, Paul James Davis
-
Publication number: 20170217983Abstract: Disclosed are compounds of formula (I): and pharmaceutically acceptable N-oxides, salts, hydrates, solvates, complexes, bioisosteres, metabolites, and prodrugs thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: ApplicationFiled: January 29, 2016Publication date: August 3, 2017Applicant: Summit Therapeutics PLCInventors: Peter David Johnson, Richard John Vickers, Francis Xavier Wilson, Colin Richard Dorgan, Lauren Jayne Sudlow, Stephen Paul Wren, Renate Maria van Well
-
Publication number: 20160184283Abstract: Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.Type: ApplicationFiled: March 8, 2016Publication date: June 30, 2016Inventors: Francis Xavier WILSON, Peter David JOHNSON, Richard VICKERS, Richard STORER, Graham Michael WYNNE, Alan Geoffrey ROACH, Olivier DE MOOR, Colin Richard DORGAN, Paul James DAVIS
-
Publication number: 20160145266Abstract: Disclosed are compounds of formula (I): and pharmaceutically acceptable N-oxides, salts, hydrates, solvates, complexes, bioisosteres, metabolites, and prodrugs thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: ApplicationFiled: January 29, 2016Publication date: May 26, 2016Applicant: Summit Therapeutics PLCInventors: Peter David Johnson, Richard John Vickers, Francis Xavier Wilson, Colin Richard Dorgan, Lauren Jayne Sudlow, Stephen Paul Wren, Renate Maria van Well
-
Patent number: 9314456Abstract: Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.Type: GrantFiled: February 6, 2015Date of Patent: April 19, 2016Assignee: SUMMIT THERAPEUTICS PLCInventors: Francis Xavier Wilson, Peter David Johnson, Richard Vickers, Richard Storer, Graham Michael Wynne, Alan Geoffrey Roach, Olivier De Moor, Colin Richard Dorgan, Paul James Davis
-
Patent number: 9278091Abstract: Disclosed are compounds of formula (I): and pharmaceutically acceptable N-oxides, salts, hydrates, solvates, complexes, bioisosteres, metabolites, and prodrugs thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: GrantFiled: February 12, 2015Date of Patent: March 8, 2016Assignee: Summit Therapeutics PLCInventors: Peter David Johnson, Richard John Vickers, Francis Xavier Wilson, Colin Richard Dorgan, Lauren Jayne Sudlow, Stephen Paul Wren, Renate Maria van Well
-
Publication number: 20150209340Abstract: Disclosed are compounds of formula (I): and pharmaceutically acceptable N-oxides, salts, hydrates, solvates, complexes, bioisosteres, metabolites, and prodrugs thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: ApplicationFiled: February 12, 2015Publication date: July 30, 2015Applicant: Summit Corporation PlcInventors: Peter David Johnson, Richard John Vickers, Francis Xavier Wilson, Colin Richard Dorgan, Lauren Jayne Sudlow, Stephen Paul Wren, Renate Maria van Well
-
Publication number: 20150150861Abstract: Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.Type: ApplicationFiled: February 6, 2015Publication date: June 4, 2015Inventors: Francis Xavier WILSON, Peter David Johnson, Richard Vickers, Richard Storer, Graham Michael Wynne, Alan Geoffrey Roach, Olivier De Moor, Colin Richard Dorgan, Paul James Davis
-
Patent number: 8987308Abstract: Disclosed are compounds of formula (I): or a pharmaceutically acceptable N-oxide, salt, hydrate, solvate, complex, bioisostere, metabolite or prodrug thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: GrantFiled: November 30, 2012Date of Patent: March 24, 2015Assignee: Summit Corporation PlcInventors: Peter David Johnson, Richard John Vickers, Francis Xavier Wilson, Colin Richard Dorgan, Lauren Jayne Sudlow, Stephen Paul Wren, Renate van Well
-
Patent number: 8975416Abstract: Disclosed are compounds of formula (I), which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.Type: GrantFiled: December 1, 2009Date of Patent: March 10, 2015Assignee: Summit Corporation PLCInventors: Paul James Davis, Olivier De Moor, Colin Richard Dorgan, Peter David Johnson, Alan Geoffrey Roach, Richard Storer, Richard John Vickers, Francis Xavier Wilson, Graham Michael Wynne
-
Publication number: 20140073801Abstract: Disclosed are compounds of formula (I): or a pharmaceutically acceptable salt, derivative, solvate, isomer, tautomer, N-oxide, ester, prodrug, isotope or protected form thereof, which are of use as OGA inhibitors, for example in the treatment of various conditions and diseases, including neurodegenerative disorders.Type: ApplicationFiled: August 29, 2013Publication date: March 13, 2014Inventors: Richard Storer, Jonathon Mark Tinsley, Francis Xavier Wilson, Graeme Horne, Stephen Paul Wren, Colin Richard Dorgan, Renate Maria van Well, Lindsay Fowler, Louise Czemerys
-
Publication number: 20140018320Abstract: There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C?W, NR4, NC(?O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents -L-R3, in which L is a single bond or a linker group, additionally, R1, R3-R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent paiType: ApplicationFiled: July 11, 2013Publication date: January 16, 2014Applicant: Summit Corporation PLCInventors: GRAHAM MICHAEL WYNNE, STEPHEN PAUL WREN, PETER DAVID JOHNSON, PAUL DAMIEN PRICE, OLIVIER DE MOOR, GARY NUGENT, RICHARD STORER, RICHARD JOSEPH PYE, COLIN RICHARD DORGAN
-
Publication number: 20140011782Abstract: Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.Type: ApplicationFiled: June 7, 2013Publication date: January 9, 2014Inventors: Graham Michael WYNNE, Stephen Paul WREN, Peter David JOHNSON, Paul Damien PRICE, Olivier DE MOOR, Gary NUGENT, Richard STORER, Richard Joseph PYE, Colin Richard DORGAN
-
Publication number: 20130309191Abstract: Disclosed are compounds of formula (I): or a pharmaceutically acceptable N-oxide, salt, hydrate, solvate, complex, bioisostere, metabolite or prodrug thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: ApplicationFiled: November 30, 2012Publication date: November 21, 2013Inventors: Peter David Johnson, Richard John Vickers, Francis Xavier Wilson, Colin Richard Dorgan, Lauren Jayne Sudlow, Stephen Paul Wren, Renate Van Well
-
Patent number: 8518980Abstract: There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C?W, NR4, NC(?O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents -L-R3, in which L is a single bond or a linker group, additionally, R1, R3-R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent paiType: GrantFiled: February 9, 2007Date of Patent: August 27, 2013Assignee: Summit Corporation PLCInventors: Graham Michael Wynne, Stephen Paul Wren, Peter David Johnson, Paul Damien Price, Olivier De Moor, Gary Nugent, Richard Storer, Richard Joseph Pye, Colin Richard Dorgan
-
Patent number: 8501713Abstract: Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.Type: GrantFiled: August 1, 2008Date of Patent: August 6, 2013Assignee: Summit Corporation PLCInventors: Graham Michael Wynne, Stephen Paul Wren, Peter David Johnson, Paul Damien Price, Olivier De Moor, Gary Nugent, Richard Storer, Richard Joseph Pye, Colin Richard Dorgan
-
Patent number: 8268878Abstract: Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.Type: GrantFiled: July 11, 2011Date of Patent: September 18, 2012Assignee: Oxagen LimitedInventors: Richard Edward Armer, Graham Michael Wynne, Colin Richard Dorgan, Peter David Johnson
-
Patent number: 8168673Abstract: Compounds of general formula (I) wherein W is chloro or fluoro; Z is a group SO2R1; wherein R1 is —C3-C8 cycloalkyl or heterocyclyl optionally substituted with one or more substituents chosen from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, and —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.Type: GrantFiled: January 22, 2009Date of Patent: May 1, 2012Assignee: Oxagen LimitedInventors: Richard Edward Armer, Carole Eliane Andree Maillol, Colin Richard Dorgan, Graham Michael Wynne, Julia Vile
-
Publication number: 20120020950Abstract: Disclosed are compounds of formula (I), which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.Type: ApplicationFiled: December 1, 2009Publication date: January 26, 2012Inventors: Paul James Davis, Olivier De Moor, Colin Richard Dorgan, Peter David Johnson, Alan Geoffrey Roach, Richard Storer, Richard John Vickers, Francis Xavier Wilson, Graham Michael Wynne
-
Publication number: 20110268693Abstract: Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.Type: ApplicationFiled: July 11, 2011Publication date: November 3, 2011Applicant: Oxagen LimitedInventors: Richard Edward ARMER, Graham Michael Wynne, Colin Richard Dorgan, Peter David Johnson